The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?

The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?

Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) show cardiovascular protective effects, regardless of the patient’s history of diabetes mellitus (DM). SGLT2is suppressed cardiovascular adverse events in patients with type 2 DM, and furthermore, SGLT-2is reduced the risk of worsening heart failu...

Full description

Bibliographic Details
Main Authors: Ayami Naito, Yuji Nagatomo, Akane Kawai, Midori Yukino-Iwashita, Ryota Nakazawa, Akira Taruoka, Asako Takefuji, Risako Yasuda, Takumi Toya, Yukinori Ikegami, Nobuyuki Masaki, Yasuo Ido, Takeshi Adachi
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Journal of Personalized Medicine
Subjects:
sodium-glucose cotransporter-2 (SGLT-2) inhibitors
heart failure
frailty
sarcopenia
Online Access:https://www.mdpi.com/2075-4426/14/2/141

Similar Items

Similar Items